$AXTI

The article says AI optics supply is constrained by China-controlled export licensing for indium-phosphide wafers used in data-center lasers. Lumentum (LITE) agreed to pay AXT (AXTI) $87M for six years of wafer supply, but AXT’s shipments depend on permits from Beijing’s Ministry of Commerce. It cites Reuters on possible FCC rules limiting Chinese optical transceivers and notes large stock swings for LITE, COHR, and AAOI.

Simply Wall St reports AXT (AXTI) Q2 2026 results, citing record indium phosphide revenue linked to AI data center demand and new long-term supply deals with Lumentum, Coherent, and Casella. The stock surged, with 7-day return of 85.58% and YTD return of 309.37%. The article contrasts a $96.50 fair value narrative with a $68.61 close and notes export-permit delays and China customer concentration risks.

The article says U.S. lawmakers urged Apple to avoid using CXMT and YMTC memory chips in China-only devices. It also cites CHIPS Act incentives totaling $874 million for seven AI and HPC semiconductor firms, and DOT changes granting Zoox a temporary autonomous-vehicle exemption. It reports Apple Q3 EPS $2.02 vs $1.89, and Amazon Q2 revenue $200.61B vs $196.46B, EPS $5.75 vs $1.82, plus multiple other company earnings and guidance updates.

AXT (AXTI) reported strong Q2 results with record revenue, profit, and net income, citing high demand for indium phosphide substrates used in AI datacenter infrastructure. The company expanded capacity and expects continued multi-year demand, supported by three supply agreements. The article notes the stock is up despite being below its all-time high.

Investing.com’s Wall Street analyst recap covers Huntington Bancshares (BofA cuts to Neutral, PT $18.50), Clorox (Jefferies cuts to Hold, expects FY27 guidance ~6% below consensus), Ribbon Communications (B. Riley upgrades to Buy, PT $3.30), New Oriental Education (Macquarie keeps Neutral, PT up 15% citing $500M capital returns), and AXT (Needham upgrades to Buy, PT $90).

AXT (AXTI) held its Q2 2026 earnings call, reporting revenue of $47.6M, up 77% vs Q1 2026 and 164% vs Q2 2025. Indium phosphide revenue was $30.7M. Non-GAAP gross margin was 45.0%. Non-GAAP net profit was $11.9M ($0.19/share). Cash rose to $749M after a $632M secondary offering. The company also discussed supply prepayments and a plan to list its Tongmei subsidiary via Hong Kong instead of China’s STAR Market.

AXT (AXTI) shares rose 28.7% to $60.43 after the company reported Q2 results. According to AXT, Q2 revenue was $47.6m versus $18.0m a year earlier, with net profit of $11.1m versus a loss, and basic EPS of $0.18. Non-GAAP gross margin rose to 45% from 8.2%, driven by indium phosphide revenue and AI demand.

U.S. equities trade choppily as bond yields stay elevated, with the 10-year yield above 4.7% cited. The article notes Amazon.com (AMZN) shares up about 15% after upbeat earnings and heavy options activity, while Apple (AAPL) is down despite revenue topping expectations. It also highlights AXT Inc (AXTI) up about 26% after a record revenue beat and a long-term supplier agreement with Lumentum (LITE).

AXT Inc. (NASDAQ:AXTI) shares rose premarket after the company reported Q2 results. Adjusted EPS was 19 cents, above the 7-cent consensus. Revenue increased 164.8% Y/Y to $47.59 million versus $34.09 million expected. Indium phosphide revenue reached a record $30.7 million, and Q3 guidance calls for adjusted EPS of 30-32 cents and sales of $66.0 million.

RTTNews reports notable premarket moves ahead of Friday’s open, highlighting gainers including REPL (+131% to $12.49), AXT (+34% to $62.94), COHU (+24% to $57.70) and NWL (+19% to $6.11). Losers include BIOA (-53% to $11.64), DFNS (-49% to $43.50), GLUE (-29% to $16.00) and PN (-27% to $17.20).